Literature DB >> 7710151

Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen.

S R Thom1, R L Taber, I I Mendiguren, J M Clark, K R Hardy, A B Fisher.   

Abstract

STUDY
OBJECTIVE: Carbon monoxide (CO) poisoning is a major clinical problem. The risk of morbidity and the most effective treatment have not been clearly established. We measured the incidence of delayed neurologic sequelae (DNS) in a group of patients acutely poisoned with CO and tested the null hypothesis that the incidence would not be affected by treatment with hyperbaric oxygen (HBO).
DESIGN: We conducted a prospective, randomized study in patients with mild to moderate CO poisoning who presented within 6 hours. Patients had no history of loss of consciousness or cardiac instability.
INTERVENTIONS: The incidence of DNS was compared between groups treated with ambient pressure 100% oxygen or HBO (2.8 ATA for 30 minutes followed by 2.0 ATA oxygen for 90 minutes). DNS were defined as development of new symptoms after oxygen treatment plus deterioration on one or more subtests of a standardized neuropsychologic screening battery.
RESULTS: In 7 of 30 patients (23%), DNS developed after treatment with ambient-pressure oxygen, whereas no sequelae developed in 30 patients after HBO treatment (P < .05). DNS occurred 6 +/- 1 (mean +/- SE) days after poisoning and persisted 41 +/- 8 days. At follow-up 4 weeks after poisoning, patients who had been treated with ambient pressure oxygen and had not sustained DNS exhibited a worse mean score on one subtest, Trail Making, compared with the group treated with HBO and with a control group matched according to age and education level. There were no differences in scores between the control group and the hyperbaric oxygen group.
CONCLUSION: DNS after CO poisoning cannot be predicted on the basis of a patient's clinical history or CO level. HBO treatment decreased the incidence of DNS after CO poisoning.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  1995        PMID: 7710151     DOI: 10.1016/s0196-0644(95)70261-x

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  65 in total

Review 1.  Management of self poisoning.

Authors:  A L Jones; G Volans
Journal:  BMJ       Date:  1999-11-27

2.  Carbon monoxide poisoning.

Authors:  E Walker; A Hay
Journal:  BMJ       Date:  1999-10-23

3.  Hyperbaric oxygen in carbon monoxide poisoning.

Authors:  L K Weaver
Journal:  BMJ       Date:  1999-10-23

Review 4.  Carbon monoxide poisoning: an update.

Authors:  M Turner; M R Hamilton-Farrell; R J Clark
Journal:  J Accid Emerg Med       Date:  1999-03

5.  Hyperbaric oxygen in carbon monoxide poisoning. Authors of study clarify points that they made.

Authors:  C D Scheinkestel; D V Tuxen; M Bailey; P S Myles; K Jones; D J Cooper; I L Millar
Journal:  BMJ       Date:  2000-07-08

Review 6.  [Inhalation injury--epidemiology, diagnosis and therapy].

Authors:  Ulrich Thaler; Paul Kraincuk; Lars-Peter Kamolz; Manfred Frey; Philipp G H Metnitz
Journal:  Wien Klin Wochenschr       Date:  2010-01       Impact factor: 1.704

Review 7.  Hyperbaric oxygen for carbon monoxide poisoning.

Authors:  Nick A Buckley; David N Juurlink; Geoff Isbister; Michael H Bennett; Eric J Lavonas
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 8.  Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy.

Authors:  Jason J Rose; Ling Wang; Qinzi Xu; Charles F McTiernan; Sruti Shiva; Jesus Tejero; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

9.  Carbon monoxide inhalation increases microparticles causing vascular and CNS dysfunction.

Authors:  Jiajun Xu; Ming Yang; Paul Kosterin; Brian M Salzberg; Tatyana N Milovanova; Veena M Bhopale; Stephen R Thom
Journal:  Toxicol Appl Pharmacol       Date:  2013-09-30       Impact factor: 4.219

Review 10.  Carbon monoxide poisoning (acute).

Authors:  Kent Olson; Craig Smollin
Journal:  BMJ Clin Evid       Date:  2008-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.